These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 10591710)

  • 1. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.
    Forbes RB; Lees A; Waugh N; Swingler RJ
    BMJ; 1999 Dec; 319(7224):1529-33. PubMed ID: 10591710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis.
    Touchette DR; Durgin TL; Wanke LA; Goodkin DE
    Clin Ther; 2003 Feb; 25(2):611-34. PubMed ID: 12749517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain.
    Dembek C; White LA; Quach J; Szkurhan A; Rashid N; Blasco MR
    Eur J Health Econ; 2014 May; 15(4):353-62. PubMed ID: 23615954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis.
    Nuijten MJ; Hutton J
    Value Health; 2002; 5(1):44-54. PubMed ID: 11873383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
    Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC
    Value Health; 2004; 7(5):554-68. PubMed ID: 15367251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.
    Pan F; Goh JW; Cutter G; Su W; Pleimes D; Wang C
    Clin Ther; 2012 Sep; 34(9):1966-76. PubMed ID: 22906738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life.
    Parkin D; Jacoby A; McNamee P; Miller P; Thomas S; Bates D
    J Neurol Neurosurg Psychiatry; 2000 Feb; 68(2):144-9. PubMed ID: 10644777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis.
    Kobelt G; Jönsson L; Henriksson F; Fredrikson S; Jönsson B
    Int J Technol Assess Health Care; 2000; 16(3):768-80. PubMed ID: 11028132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon beta in multiple sclerosis.
    Richards RG
    BMJ; 1996 Nov; 313(7066):1159. PubMed ID: 8916730
    [No Abstract]   [Full Text] [Related]  

  • 11. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment of multiple sclerosis with interferon-beta may be cost effective.
    Kendrick M; Johnson KI
    Pharmacoeconomics; 2000 Jul; 18(1):45-53. PubMed ID: 11010603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data.
    Kobelt G; Jönsson L; Miltenburger C; Jönsson B
    Int J Technol Assess Health Care; 2002; 18(1):127-38. PubMed ID: 11987436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition.
    Janković SM; Kostić M; Radosavljević M; Tesić D; Stefanović-Stoimenov N; Stevanović I; Raković S; Aleksić J; Folić M; Aleksić A; Mihajlović I; Biorac N; Borlja J; Vucković R
    Vojnosanit Pregl; 2009 Jul; 66(7):556-62. PubMed ID: 19678581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis.
    Caloyeras JP; Zhang B; Wang C; Eriksson M; Fredrikson S; Beckmann K; Knappertz V; Pohl C; Hartung HP; Shah D; Miller JD; Sandbrink R; Lanius V; Gondek K; Russell MW
    Clin Ther; 2012 May; 34(5):1132-44. PubMed ID: 22541587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
    Gani R; Giovannoni G; Bates D; Kemball B; Hughes S; Kerrigan J
    Pharmacoeconomics; 2008; 26(7):617-27. PubMed ID: 18563952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.
    Wright M; Grieve R; Roberts J; Main J; Thomas HC;
    Health Technol Assess; 2006 Jul; 10(21):1-113, iii. PubMed ID: 16750059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
    Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
    J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of Avonex (interferon beta-Ia) in patients following a single demyelinating event.
    Iskedjian M; Walker JH; Gray T; Vicente C; Einarson TR; Gehshan A
    Mult Scler; 2005 Oct; 11(5):542-51. PubMed ID: 16193892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates.
    Brown MG; Murray TJ; Sketris IS; Fisk JD; LeBlanc JC; Schwartz CE; Skedgel C
    Int J Technol Assess Health Care; 2000; 16(3):751-67. PubMed ID: 11028131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.